

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923

POLYMED
MEDICAL DEVICES

We Care As We Cure

Date: 08th August 2023

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Submission of Newspaper Publication Cutting

Dear Sir/Madam,

Pursuant to Regulation 47 and other applicable provisions of SEBI (LODR) Regulations, 2015, we are enclosing herewith copies of Newspaper publication of Unaudited Financial Results for the Quarter ended June 30, 2023, published in Financial Express and Jansatta on August 8, 2023.

The Board Meeting in which the aforesaid unaudited financial results were approved was held on August 7, 2023, which commenced at 10:30 am and concluded at 12:00 pm.


Further, this is to inform that the Trading Window of the Company, which was closed w.e.f. July 01, 2023, shall open on August 10, 2023, i.e. after the end of 48 hours from the declaration of unaudited financial results for the quarter ended June 30, 2023.

Kindly take note of the same.

Thanking You,

Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary



1. The above is an extract of the detailed format of Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2023 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Bombay Stock Exchange website (www.bseindia.com) and on the Company's website (www.kgdenim.com)
2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 7th August, 2023 and subject to limited review by the Statutory Auditor of the Company.

Place : Coimbatore
Date : 07.08.2023

For K G DENIM LIMITED
KG BAALAKRISHNAN
Executive Chairman DIN : 00002



POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020
CIN: L40300DL1995PLC066923, Phone: 011-26321889, Fax: 011-26321894
Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(₹ in lacs except per share data)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter Ended	Quarter Ended	Year Ended	Quarter Ended	Quarter Ended	Year Ended
		30.06.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)	30.06.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Total Income from operations	31,872.79	24,358.45	110,433.24	33,394.49	25,342.42	115,141.58
2	Net Profit/(Loss) for the period (before tax, Exceptional and/or Extraordinary items)	8,086.80	3,812.90	23,682.71	8,304.07	3,629.13	23,749.14
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	8,086.80	3,812.90	23,682.71	8,304.07	3,629.13	23,749.14
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	6,052.42	2,880.00	17,904.47	6,269.56	2,696.23	17,928.25
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,043.03	2,898.74	17,919.29	6,245.67	2,700.54	17,968.86
6	Equity paid up share capital	4,797.23	4,795.02	4,797.23	4,797.23	4,795.02	4,797.23
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year			118,615.22			119,365.49
8	Earnings per share (Face value of ₹ 5 Each) (Quarterly not annualised):						
	Basic (₹)	6.31	3.00	18.67	6.54	2.81	18.69
	Diluted (₹)	6.30	3.00	18.65	6.53	2.81	18.67

Notes:

1. The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 7th August, 2023 and have also been limited reviewed by Statutory auditors of the Company.
2. The above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.

Place: New Delhi
Date : 7th August 2023

By order of the Board
Sd/-
Himanshu Baid
Managing Director

Place: Kolkata Arvind Kumar Lohia
Date: 07.08.2023 Managing Director
The Notice is also available on the Company's website at www.captain.com and on the Stock Exchange website at www.cse-india.com.



CAPTAIN POLYPLAST LTD.

e-mail : info@captainpolyplast.in
web : www.captainpolyplast.com
CIN No. : L25209GJ1997PLC031985

NOTICE

Pursuant to regulation 29 of the SEBI LODR 2015, notice is hereby given that the meeting of board of directors of the company will be held on Monday, 14th August 2023 interalia,

- To consider the standalone & consolidated unaudited financial results for the quarter ended on 30th JUNE, 2023.
- To consider appointment of additional (independent non executive) director.
- To consider reappointment of managing director for further term of five years.

The said notice can be accessed on the website of the company at www.captainpolyplast.com and may also be accessed on the stock exchange website at www.bseindia.com.

Place: Rajkot
Date : 07/08/2023

For, Captain Polyplast Ltd
Sd/
Khyati Mehta
(Company Secretary)

THE
BUSINESS
DAILY.

FINANCIAL EXPRESS

FOR
DAILY
BUSINESS.

financialexpress.com

क्र. सं.	30 जून, 2022	31 मार्च, 2023
(देखें)	(अंकित)	(अंकित)
77.35	309.51	1351.59
17.66	249.81	1132.76
7.61	33.58	83.20
6.84	22.55	57.37

निदेशक मंडल के लिए तथा उनकी ओर से
रेटर्न ट्रेवल टेकनोलॉजीज लिमिटेड
हस्ता./-
भानु चोपड़ा
(अध्यक्ष तथा प्रबंध निदेशक)

क) मूल (रु. में)	0.01	(0.47)	(0.01)	(0.49)
ख) तरल (रु. में)	0.01	(0.47)	(0.01)	(0.49)

टिप्पणी: 30 जून, 2023 को समाप्त तिमाही के दौरान कोई विशिष्ट मद नहीं है।
उपरोक्त सेबी (सूचीबद्धता एवं अन्य प्रकटन अपेक्षा), 2015 के विनियमन 33 के अंतर्गत स्टॉक एक्सचेंजों में दाखिल की गई तिमाही तथा वार्षिक वित्तीय परिणामों के विस्तृत प्रारूप का सार है। तिमाही तथा वार्षिक वित्तीय परिणामों का सम्पूर्ण प्रारूप स्टॉक एक्सचेंजों की वेबसाइट www.nseindia.com तथा www.bseindia.com तथा कम्पनी की वेबसाइट www.landmarkproperty.in पर उपलब्ध है।

लैंडमार्क प्रॉपर्टी डेवलपमेंट कम्पनी लिमिटेड के लिए
हस्ता./-
गौरव डालमिया
अध्यक्ष एवं प्रबंध निदेशक

स्थान: नई दिल्ली
तिथि: 07 अगस्त, 2023



पॉली मेडिक्योर लिमिटेड

पंजीकृत कार्यालय : 232बी, तृतीय मंजिल, ओखला इण्डस्ट्रियल एस्टेट, फेज-III, नई दिल्ली-110020
सीआईएन : L40300DL1995PLC066923, फोन : 011-26321889, फैक्स : 011-26321894
वेबसाइट : www.polymedicure.com, ई-मेल : investorcare@polymedicure.com

30 जून, 2023 को समाप्त तिमाही हेतु अलेखापरीक्षित स्टैण्डअलोन एवं समेकित वित्तीय परिणामों का विवरण
(प्रति शेयर डेटा को छोड़कर रु. लाख में)

क्र. सं.	विवरण	स्टैण्डअलोन			समेकित		
		समाप्त तिमाही	समाप्त तिमाही	समाप्त वर्ष	समाप्त तिमाही	समाप्त तिमाही	समाप्त वर्ष
		30.06.2023 (अलेखापरीक्षित)	30.06.2022 (अलेखापरीक्षित)	31.03.2023 (लेखापरीक्षित)	30.06.2023 (अलेखापरीक्षित)	30.06.2022 (अलेखापरीक्षित)	31.03.2023 (लेखापरीक्षित)
1	प्रचालनों से सकल आय	31,872.79	24,358.45	110,433.24	33,394.49	25,342.42	115,141.58
2	अवधि हेतु कुल लाभ/(हानि) (कर, अपवादित तथा/अथवा असाधारण मदों से पूर्व)	8,086.80	3,812.90	23,682.71	8,304.07	3,629.13	23,749.14
3	कर पूर्व अवधि हेतु कुल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के पश्चात)	8,086.80	3,812.90	23,682.71	8,304.07	3,629.13	23,749.14
4	कर पश्चात अवधि हेतु कुल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के पश्चात)	6,052.42	2,880.00	17,904.47	6,269.56	2,696.23	17,928.25
5	अवधि हेतु कुल व्यापक आय [अवधि हेतु लाभ/(हानि) (कर पश्चात) तथा अन्य व्यापक आय (कर पश्चात) सहित]	6,043.03	2,898.74	17,919.29	6,245.67	2,700.54	17,968.86
6	इक्विटी प्रदत्त शेयर पूंजी	4,797.23	4,795.02	4,797.23	4,797.23	4,795.02	4,797.23
7	आरक्षितियां (पुनर्मूल्यांकन आरक्षितियों को छोड़कर) जैसा कि दत्त वर्ष के लेखापरीक्षित तुलनपत्र में प्रदर्शित है			118,615.22			119,365.49
8	आय प्रति शेयर (रु. 5 प्रत्येक का अंकित मूल्य (तिमाही वार्षिकीकृत नहीं)						
	बेसिक (रु.)	6.31	3.00	18.67	6.54	2.81	18.69
	डाइल्यूटेड (रु.)	6.30	3.00	18.65	6.53	2.81	18.67

नोट :
1. उपर्युक्त अलेखापरीक्षित स्टैण्डअलोन तथा समेकित परिणाम लेखापरीक्षा समिति द्वारा समीक्षित तथा संस्तुत किये गये और 7 अगस्त, 2023 को आयोजित अपनी सम्बद्ध बैठक में निदेशक मण्डल द्वारा अनुमोदित किये गये और साथ ही कम्पनी के सांविधिक लेखापरीक्षकों ने भी इसको सीमित समीक्षा की है।
2. उपर्युक्त सेबी (सूचीबद्धता एवं अन्य प्रकटन अपेक्षाएँ) विनियम, 2015 के विनियमन 33 के तहत स्टॉक एक्सचेंज के पास दर्ज 30 जून, 2023 को समाप्त तिमाही हेतु अलेखापरीक्षित स्टैण्डअलोन एवं समेकित वित्तीय परिणामों के विस्तृत प्रारूप का सारांश है। अलेखापरीक्षित वित्तीय परिणामों का पूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइट www.bseindia.com, www.nseindia.com तथा कम्पनी की वेबसाइट www.polymedicure.com पर उपलब्ध है।

स्थान : नई दिल्ली
तिथि : 07 अगस्त, 2023

हस्ता./-
हिमांशु वैद
प्रबन्ध निदेशक